Primidone

Base Information Edit

Chemical Name:Primidone
CAS No.:125-33-7
Molecular Formula:C12H14N2O2
Molecular Weight:218.255
Hs Code.:29335990
European Community (EC) Number:204-737-0
NSC Number:757291,41701
UN Number:3249
UNII:13AFD7670Q
DSSTox Substance ID:DTXSID7023510
Nikkaji Number:J3.260C
Wikipedia:Primidone
Wikidata:Q420383
NCI Thesaurus Code:C47686
RXCUI:8691
Pharos Ligand ID:8YMDC812PJGZ
Metabolomics Workbench ID:43086
ChEMBL ID:CHEMBL856
Mol file:125-33-7.mol

Synonyms:Apo Primidone;Apo-Primidone;Desoxyphenobarbital;Liskantin;Misodine;Mizodin;Mylepsinum;Mysoline;Primaclone;Primidon Holsten;Primidone;Resimatil;Sertan

Suppliers and Price of Primidone

Supply Marketing:Edit

Business phase:: The product has achieved commercial mass production^*data from LookChem market partment

Manufacturers and distributors:

Manufacture/Brand
Chemicals and raw materials
Packaging
price

Usbiological
Primidone
100mg
$ 310.00

TRC
Primidone
5g
$ 70.00

TRC
Primidone
100mg
$ 50.00

TCI Chemical
Primidone >98.0%(HPLC)(N)
25g
$ 121.00

TCI Chemical
Primidone >98.0%(HPLC)(N)
5g
$ 42.00

Sigma-Aldrich
Primidone analytical standard
5g
$ 46.70

Sigma-Aldrich
Primidone solution 1.0?mg/mL in methanol, ampule of 1?mL, certified reference material, Cerilliant?
1 mL
$ 56.80

Sigma-Aldrich
Primidone solution 1.0mg/mL in methanol, ampule of 1mL, certified reference material
075-1ml
$ 55.00

Sigma-Aldrich
Primidone European Pharmacopoeia (EP) Reference Standard
$ 190.00

Sigma-Aldrich
Primidone for peak identification European Pharmacopoeia (EP) Reference Standard
y0000369
$ 190.00

Total 100 raw suppliers

Chemical Property of Primidone Edit

Chemical Property:

Appearance/Colour:Crystalline solid
Vapor Pressure:6.08E-11mmHg at 25°C
Melting Point:281-282 °C
Refractive Index:1.528
Boiling Point:520.7 °C at 760 mmHg
PKA:12.26±0.40(Predicted)
Flash Point:228.2 °C
PSA：58.20000
Density:1.138 g/cm³
LogP:1.19550
Storage Temp.:Store at RT
Solubility.:Very slightly soluble in water, slightly soluble in ethanol (96 per cent). It dissolves in alkaline solutions.
Water Solubility.:<0.1 g/100 mL at 19℃
XLogP3:0.9
Hydrogen Bond Donor Count:2
Hydrogen Bond Acceptor Count:2
Rotatable Bond Count:2
Exact Mass:218.105527694
Heavy Atom Count:16
Complexity:279
Transport DOT Label:Poison

Purity/Quality:

99% ^*data from raw suppliers

Primidone ^*data from reagent suppliers

Safty Information:

Pictogram(s): Xn
Hazard Codes:Xn,T,F
Statements: 22-40-39/23/24/25-23/24/25-11
Safety Statements: 22-36-45-36/37-16-7

MSDS Files:

SDS file from LookChem

Total 1 MSDS from other Authors

Useful:

Drug Classes:Anticonvulsants
Canonical SMILES:CCC1(C(=O)NCNC1=O)C2=CC=CC=C2
Recent ClinicalTrials:Pathophysiology of Tremor-modulating Mechanisms of Propranolol and Primidone in Essential Tremor
Description Primidone is chemically and structurally similar to phenobarbital with the exception that the carbonyl group on C2 is replaced by a methylene group. This modification leads to the production of a drug with strong anticonvulsant properties without expressed soporific effects. Primidone (Item No. 19277) is an analytical reference material categorized as a barbiturate that can be detected in urine. The physiological and toxicological properties of this compound are not known; however, it is presumed to be a modulator of GABAA receptors. This product is intended for research and forensic applications.
Uses Primidone is mainly used for major attacks. Primidone is an Anticonvulsant. Anticonvulsant
Clinical Use Primidone is the 2-deoxy derivative of phenobarbital and is approved by the U.S. FDA for initial or adjunctive treatment of simple partial, complex partial, and tonic-clonic seizures. It is less effective against these types of seizures than is phenytoin or CBZ, and it shares the antiseizure and sedative actions of phenobarbital. Although not approved for the purpose, it often is used to treat benign familial tremor (essential tremor).
Drug interactions Potentially hazardous interactions with other drugs Aminophylline and theophylline: metabolism of aminophylline and theophylline increased, reduced effect. Anthelmintics: concentration of albendazole and praziquantel reduced. Anti-arrhythmics: reduced concentration of disopyramide and possibly propafenone; possibly reduced concentration of dronedarone - avoid. Antibacterials: reduced concentration of chloramphenicol, doxycycline, metronidazole, telithromycin and rifampicin - avoid with telithromycin. Anticoagulants: increased metabolism of coumarins (reduced effect); possibly reduced concentration of apixaban and edoxaban and possibly rivaroxaban. Antidepressants: antagonise anticonvulsant effect; reduces concentration of paroxetine, reboxetine, mianserin and tricyclics; concentration reduced by St John’s wort - avoid. Antiepileptics: concentration increased by fosphenytoin, oxcarbazepine, phenytoin, stripentol and valproate and possibly carbamazepine, also active metabolite of oxcarbazepine reduced and valproate concentration reduced, concentration of fosphenytoin and phenytoin usually reduced but can also be increased; concentration of ethosuximide, rufinamide and topiramate possibly reduced; concentration of lamotrigine, tiagabine and zonisamide reduced. Antifungals: possibly reduced concentration of isavuconazole, itraconazole, posaconazole and voriconazole - avoid concomitant use with voriconazole; reduced absorption of griseofulvin (reduced effect). Antimalarials: avoid with piperaquine with artenimol; anticonvulsant effect antagonised by mefloquine Antipsychotics: antagonise anticonvulsant effect; metabolism of haloperidol increased; possibly reduces aripiprazole concentration - increase aripiprazole dose; concentration of both drugs reduced with chlorpromazine; possibly reduces clozapine concentration; possibly reduces lurasidone concentration - avoid. Antivirals: concentration of abacavir, boceprevir, darunavir, dolutegravir, fosamprenavir, indinavir, lopinavir, rilpivirine and saquinavir possibly reduced; avoid with boceprevir and rilpivirine; concentration of daclatasvir, dasabuvir, ombitasvir, paritaprevir and simeprevir possibly reduced - avoid; avoid with elvitegravir, etravirine, ledipasvir, sofosbuvir and telaprevir. Calcium-channel blockers: effects of calcium-channel blockers probably reduced - avoid with isradipine and nimodipine. Cannabis extract: concentration possibly reduced by primidone - avoid. Ciclosporin: reduced ciclosporin levels. Cobicistat: concentration of cobicistat possibly reduced. Corticosteroids: metabolism of corticosteroids accelerated, reduced effect. Cytotoxics: possibly reduced concentration of axitinib, increase axitinib dose; possibly reduced concentration of bortezomib, bosutinib, cabozantinib, ceritinib, crizotinib, dasatinib, ponatinib and vandetanib - avoid; avoid with cabazitaxel, dabrafenib, gefitinib and panobinostat; concentration of irinotecan and its active metabolite and possibly etoposide reduced; possible increased hypersensitivity reactions with procarbazine. Diuretics: concentration of eplerenone reduced - avoid; increased risk of osteomalacia with carbonic anhydrase inhibitors. Guanfacine: concentration of guanfacine possibly reduced - increase dose of guanfacine. Hormone antagonists: possibly reduced concentration of abiraterone - avoid; metabolism of toremifene accelerated.

Technology Process of Primidone

There total 13 articles about Primidone which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield: 81.0%